Full-Time

Senior Manager Supply Chain

Logistics and Inventory

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

501-1,000 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$158k - $198kAnnually

+ Equity Awards + Benefits + Learning and Development Opportunities

Senior

San Carlos, CA, USA

This is a hybrid position, requiring some in-office days at the headquarters in Redwood City, CA.

Category
Inventory Management
Supply Chain Management
Operations & Logistics
Required Skills
Supply Chain Management
Inventory Management
Data Analysis

You match the following Revolution Medicines's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • B.Sc. or M.Sc. in Supply Chain Management, Engineering, Business, Accounting/Finance, or related field with 8+ years of experience in pharmaceutical logistics and inventory management.
  • Experience in Supply Chain processes is strongly preferred.
  • Experience in implementing and managing inventory management systems (i.e., ERP).
  • Experience in commercial product launch preparation and execution.
  • Experience in contract packaging and 3PL distribution operation.
  • Experience in developing, negotiating, and executing master service agreements.
  • Experience managing, analyzing, and communicating results to senior leadership.
  • Experience implementing repeatable processes and driving automation or standardization.
  • Experience defining program requirements and using data and metrics to determine improvements.
  • Experience managing both strategic and tactical/operational projects.
  • Working knowledge of GMP and GDP.
  • Working knowledge of end-to-end pharmaceutical supply chain and demand/supply planning.
  • Working knowledge of small molecule drug development and commercialization.
  • Working knowledge of pharmaceutical commercial manufacturing, regulatory, and quality assurance.
  • Working knowledge of customs regulations and international trade compliance.
  • Working knowledge of dangerous goods / hazardous material transportation regulations, classifications, packaging, and transit requirements e.g. IATA, DOT, hazmat.
  • Strong negotiation skills.
  • Solid project management, facilitation, and problem-solving skills.
  • Solid organizational and time management skills.
  • Strong communicator and connector between Commercial, Finance, Quality, Regulatory, and Supply Chain teams.
  • Effective, open, and transparent communication skills (verbal and written).
  • Capable of working on multiple projects/tasks and able to meet timelines.
  • Self-starter with a high level of comfort with ambiguity and complexity and the ability to multi-task while consistently delivering quality results.
  • A team-oriented progressive thinker who enjoys participating in an innovative and creative work environment.
Responsibilities
  • Serve as the subject matter expert for all logistics matters for RevMed.
  • Ensure all supplies are controlled and distributed in accordance with Good Manufacturing Practices (GMP), Good Clinical Practices (GCP), and Good Distribution Practices (GDP).
  • Manage global logistics and distribution of finished drug products and all intermediates.
  • Evaluate, select, onboard, and manage freight forwarders and warehousing depot services to support RevMed’s commercial supply chain.
  • Manage shipping validation to support NDA filing.
  • Develop, maintain, and enforce logistics management business processes and/or SOPs.
  • Ensure optimized and compliant transportation of goods.
  • Create and manage internal reports for key logistics costs such as storage costs, picking costs, freight costs, cargo insurance, VAT claims, and recollection.
  • Implement and manage an inventory management system to support commercial launch.
  • Ensure reconciliation of raw materials, work-in-progress (WIP), and finished goods inventory to comply with Sarbanes’s Oxley (SOX) standards.
  • Develop and implement strategies to maintain optimal inventory levels, balancing supply with production and sales demand.
  • Generate and analyze reports on inventory levels, usage, and forecasts, providing insights to management.
  • Establish and direct cycle count programs. Investigate discrepancies and root cause analysis.
  • Establish supply chain master data and establish a program to monitor and increase accuracy.
  • Develop, maintain, and enforce inventory management business processes and/or SOPs.
  • Identify and implement process improvements to increase efficiency, reduce costs, and minimize waste.
Desired Qualifications
  • American Production and Inventory Control Society (APICS) certification.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Size

501-1,000

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Acquisition of EQRx adds over $1 billion in net cash for R&D.
  • FDA fast-tracking RAS-targeted therapies supports their pipeline development.
  • Increased interest in targeted cancer therapies boosts investment opportunities.

What critics are saying

  • Integration challenges with EQRx could disrupt operations and timelines.
  • EQRx's pricing model may conflict with Revolution Medicines' strategies.
  • $600M public stock offering may dilute existing shareholder value.

What makes Revolution Medicines unique

  • Revolution Medicines uses a unique method to synthesize pharmaceutically optimized natural compounds.
  • Their Tri Complex Inhibitor platform targets RAS proteins driving cancer growth.
  • Exclusive license with University of Illinois enhances their proprietary technology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

7%
Stock Titan
Dec 3rd, 2024
Revolution Medicines Launches $600M Public Stock Offering, Plans $90M Option | RVMD Stock News

Clinical-stage oncology company Revolution Medicines announces major public offering of common stock worth $600M, with additional $90M option for underwriters.

RevMed
Feb 21st, 2024
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | Revolution Medicines

Underwriters’ Full Exercise of Option Brings Gross Proceeds to $179.4 Million REDWOOD CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq:RVMD), a clinical-stage oncology company focused on developing targeted therapies to inhibit elusive frontier targets within

Seeking Alpha
Feb 14th, 2024
Corvex Management buys Illumina, exits Apple, TKO

Corvex Management buys Illumina, exits Apple, TKO.

GlobeNewswire
Nov 1st, 2023
Leading Independent Proxy Advisory Firms Iss And Glass Lewis Recommend Revolution Medicines Stockholders Vote “For” Proposed Acquisition Of Eqrx, Inc.

REDWOOD CITY, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that leading independent proxy advisory firms, Institutional Shareholder Services Inc. ("ISS") and Glass Lewis & Co. ("Glass Lewis"), have recommended Revolution Medicines stockholders vote “FOR” the issuance of Revolution Medicines shares in the previously announced all-stock acquisition of EQRx, Inc. at the special meeting of stockholders scheduled for November 8, 2023.In their respective reports, ISS and Glass Lewis view the proposed transaction as favorable to Revolution Medicines stockholders

PharmaSources
Aug 15th, 2023
EQRx, known as the "TEMU" of the Pharmaceutical Industry, has been Acquired by Revolution Medicines

On August 1st, EQRx announced an agreement with Revolution Medicines to be acquired in an all-stock transaction, which is expected to be completed in November 2023.